IL1B and type 2 diabetes mellitus: Canakinumab targets IL-1β–dependent inflammation, thereby potentially preserving/improving pancreatic β-cell function and inhibiting progression to atherothrombosis in the coronary arteries of T2DM patients who are at a high risk of developing cardiovascular disease.